超5亿融资！创新械企完成C轮

Core Viewpoint - Neurent Medical has completed a $74 million (approximately 510 million RMB) Series C financing, marking a transition from the "technology validation phase" to the "clinical penetration phase" following FDA 510(k) approval of its Neuromark system in 2025 [1][2]. Financing and Use of Funds - The funds will primarily be used for three areas: promoting the Neuromark system, building real-world evidence through multi-center studies, and developing new indications and product iterations [2][5]. Technology and Mechanism - Chronic rhinitis is increasingly recognized as driven by abnormal excitation of the parasympathetic nervous system rather than solely an inflammatory disease [3]. - Neuromark focuses on "functional regulation" by precisely adjusting nerve activity rather than tissue removal, addressing limitations of traditional treatment methods [4]. Engineering Design and Operation - Neuromark is an impedance-controlled radiofrequency nerve modulation system characterized by "precise positioning + controlled energy + real-time feedback" [8]. - The system features a flexible catheter design that can access narrow areas of the nasal cavity, ensuring stable contact with nerve distribution [9]. - It employs real-time impedance measurement to adjust radiofrequency power and duration, aiming to alter nerve conduction rather than burn tissue, thus reducing mucosal necrosis and postoperative pain [10]. Clinical Value and Target Population - Typical patients include those with long-term medication dependence and recurrent symptoms, with studies showing sustained symptom score reductions for over a year and potential for reduced long-term medication use [11][12]. Company Background - Neurent Medical, based in Ireland, focuses exclusively on nasal nerve modulation, differing from traditional ENT companies by establishing a comprehensive treatment pathway around a single disease [13][14]. - The development logic follows a path of accumulating evidence for a single indication, leading to guideline inclusion and payment negotiations [15]. Significance of Financing - The financing is crucial for supporting physician training and real-world data collection, which are key for integrating nerve modulation products into healthcare reimbursement systems [16]. Conclusion - For chronic rhinitis, a high-prevalence condition often managed with medication, the clinical breakthrough is expected to come from the establishment of repeatable and standardized treatment methods rather than singular technological advancements [17].